| dc.creator |
YÜREKLİ, Vedat Ali |
|
| dc.creator |
Akhan, Galip |
|
| dc.creator |
KUTLUHAN, Süleyman |
|
| dc.creator |
Uzar, Ertugrul |
|
| dc.creator |
KOYUNCUOĞLU, Hasan Rifat |
|
| dc.creator |
Gultekin, Fatih |
|
| dc.date |
2008-01-31T22:00:00Z |
|
| dc.date.accessioned |
2020-10-06T09:27:15Z |
|
| dc.date.available |
2020-10-06T09:27:15Z |
|
| dc.identifier |
1760a0e0-0b24-4fa7-94fd-8bf795aee1d7 |
|
| dc.identifier |
10.1007/s10194-008-0002-5 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/1760a0e0-0b24-4fa7-94fd-8bf795aee1d7/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/54199 |
|
| dc.description |
The objective of the study was to assess the efficacy and tolerability of sodium valproate (VPA) on chronic daily headache (CDH) in a prospective, double-blind, randomized, placebo-controlled trial. Seventy patients were included in the study. Twenty-nine had chronic migraine ( CM) and 41 had chronic tension-type headache ( CTTH). VPA and placebo were applied for 3 months to 40 and 30 patients, respectively. Visual analog scale ( VAS) and pain frequency (PF) were used for evaluation. VPA decreased the maximum pain VAS levels (MaxVAS) and PF at the end of the study ( P = 0.028 and P = 0.000, respectively), but did not change general pain VAS (GnVAS) levels ( P = 0.198). In CM patients, the decreases in MaxVAS, GnVAS and PF parameters were more in VPA treated patients ( P = 0.006, P = 0.03, and P = 0.000, respectively). VPA treatment caused more reduction in PF than placebo in the CTTH subgroup ( P = 0.000). VPA is effective in the prophylactic treatment of CDH by reducing MaxVAS levels and PF. It was more effective in CM than in CTTH. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.title |
The effect of sodium valproate on chronic daily headache and its subgroups |
|
| dc.type |
info:eu-repo/semantics/article |
|